Genetic nondiscrimination legislation: A critical prerequisite for pharmacogenomics data sharing

Pharmacogenomics

Volumn 8, Issue 5, 2007, Pages 519-

  Altman, Russ B ^a   Benowitz, Neal ^b   Gurwitz, David ^c   Lunshol, Jeantine ^d   Relling, Mary ^e   Lamba, Jatinder ^e   Wieben, Eric ^f   Mooney, Sean ^g   Giacomini, Kathleen ^b   Weiss, Scott ^h   Johnson, Julie A ⁱ   McLeod, Howard ^j   Flockhart, David ^g   Weinshilboum, Richard ^f   Shuldiner, Alan R ^k   Roden, Dan ^l   Kraus, Ronald M ^m   Ratain, Mark ⁿ  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f MAYO CLINIC   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^k UNIVERSITY OF MARYLAND   (United States)

^l VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLIZING ENZYME;

ACCESS TO INFORMATION; ALLELE; DATA MINING; DRUG TARGETING; EMPLOYMENT; GENETIC ASSOCIATION; GENETIC PRIVACY; GENOTYPE PHENOTYPE CORRELATION; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; INDIVIDUALIZATION; LAW ENFORCEMENT; MEDICAL DECISION MAKING; NOTE; PATIENT AUTONOMY; PATIENT RIGHT; PHARMACOGENOMICS; TREATMENT PLANNING;

EMPLOYMENT; GENETIC PRIVACY; GOVERNMENT REGULATION; INSURANCE; MEDICAL RECORDS; PHARMACOGENETICS; PREJUDICE; UNITED STATES;

EID: 34248578772     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.5.519     Document Type: Note

References (11)

1. GINA, aGAIN. Nat Genet. 39, 133 (2007).
2. Kohane IS, Altman RB: Health-information altruists - a potentially critical resource. N. Engl. J. Med. 353, 2074-2077 (2005).
3. Knoppers BM, Joly Y, Simard J, Durocher F: The emergence of an ethical duty to disclose genetic research results: international perspectives. Eur. J. Hum. Genet. 14, 1170-1178 (2006).
4. Lin Z, Owen AB, Altman RB: Genetics. Genomic research and human subject privacy. Science 305, 183 (2004).
5. Lunshof JE: Personalized medicine: how much can we afford? A bioethics perspective. Personalized Med. 2, 43-47 (2005).
6. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL: National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296, 1858-1866 (2006).
7. Pirmohamed M, James S, Meakin S et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. Br. Med. J. 329, 15-19 (2004).
8. Collins FS, Green ED, Guttmacher AE, Guyer MS: US National Human Genome Research Institute: a vision for the future of genomics research. Nature 422, 835-847 (2003).
9. Gurwitz D, Lunshof JE, Altman RB: A call for the creation of personalized medicine databases. Nat. Rev. Drug Discov. 5, 23-26 (2006).
10. Service RF: Gene sequencing. The race for the $1000 genome. Science 311, 1544-1546 (2006).
11. Sladek R, Rocheleau G, Rung J et al.: A genome-wide association study identifies novel risk loci for Type 2 diabetes. Nature 445, 881-885 (2007).